Client News

Laser Photonics (NASDAQ:LASE) Provides Shareholder Letter and Announces Fourth Quarter and Year-End 2023 Results

Fourth quarter revenue grew by 673% Fourth quarter operating and net losses improved by 36% and 86%, respectively ORLANDO, FL / ACCESSWIRE / April 15, 2024 / Laser Photonics Corporation (LPC) (NASDAQ:LASE), a leading global industrial developer of CleanTech Laser Systems for laser cleaning and other applications, today announced financial results for its fourth quarter and year ended […]

Pursuant to NYSE Regulations, Splash Beverage Group (NYSE American: SBEV) Acknowledges the Going Concern Language in Its 10K and Reaffirms Its Commitment to Success

FORT LAUDERDALE, FL, April 12, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”), a portfolio company of leading beverage brands, issued a statement today reaffirming its commitment to sustainable growth and long-term success despite a going concern opinion. This advisement does not represent any change or amendment to […]

Digital Brands Group (NASDAQ: DBGI) to Report Fourth Quarter and Fiscal Year 2023 Financial Results on Monday, April 15, 2024

AUSTIN, April 12, 2024 /PRNewswire/ — Digital Brands Group, Inc. (“DBG”)  (NASDAQ: DBGI), a curated collection of luxury lifestyle, digital-first brands,  will report financial results for the fourth quarter ended December 31, 2023 on Monday, April 15, 2023 at 4:30 p.m. ET. Management will host a conference call on Monday, April 15 at 5:00 p.m. ET to discuss the results. The live conference call can be accessed by […]

Longeveron (NASDAQ: LGVN) Announces Closing of $5.2 Million Public Offering

MIAMI, April 11, 2024 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced public offering of up to 2,234,043 shares […]

SciSparc (Nasdaq: SPRC) to Acquire AutoMax

TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd. (“AutoMax”), a leading […]

NKGen Biotech (Nasdaq: NKGN) Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs

The Company’s neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer’s Phase 2 trial and anticipation of Parkinson’s Phase 1/2a trial initiation. Additional financing also to support the Company’s oncology clinical program, with interim safety data readout in Q2 for its allogeneic product candidate. SANTA ANA, Calif., April 11, 2024 (GLOBE NEWSWIRE) […]

Trio Petroleum Corp (NYSE American: “TPET”) Provides Operational Update for Monterey County Oil Producing Assets

Combined Oil Production Stabilized at 75 Barrels Per Day Bakersfield, CA, April 11, 2024 (GLOBE NEWSWIRE) — Trio Petroleum Corp (NYSE American: “TPET”, “Trio” or the “Company”), a California-based oil and gas company, today provided an update on its oil producing assets in Monterey County, California, including at the Presidents Field (“Presidents”) of the South […]

Tiziana Life Sciences (Nasdaq: TLSA) Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS” that will be presented during the “Multiple […]

Skye Bioscience (OTCQB: SKYE) Uplists to The Nasdaq Global Market

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the Company has received approval […]

Start Expanding
Your Shareholder Base

Let us help you connect with investors
committed to your success.